Vital KSK Holdings, Inc. (TYO:3151)
1,526.00
-17.00 (-1.10%)
Jun 3, 2026, 1:55 PM JST
Vital KSK Holdings Revenue
In the fiscal year ending March 31, 2026, Vital KSK Holdings had annual revenue of 610.50B JPY with 1.69% growth. Vital KSK Holdings had revenue of 145.94B in the quarter ending March 31, 2026, with 4.48% growth.
Revenue
610.50B
Revenue Growth
+1.69%
P/S Ratio
0.12
Revenue / Employee
162.54M
Employees
3,756
Market Cap
74.65B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 610.50B | 10.13B | 1.69% |
| Mar 31, 2025 | 600.37B | 12.89B | 2.19% |
| Mar 31, 2024 | 587.48B | 7.71B | 1.33% |
| Mar 31, 2023 | 579.77B | 2.52B | 0.44% |
| Mar 31, 2022 | 577.25B | 40.22B | 7.49% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Takeda Pharmaceutical Company | 4.51T |
| Otsuka Holdings | 2.52T |
| Chugai Pharmaceutical | 1.29T |
| HOYA Corporation | 947.75B |
| Qol Holdings | 290.77B |
| Cawachi | 284.49B |
| KYORIN Pharmaceutical | 126.26B |
| ASKA Pharmaceutical Holdings | 71.13B |